Compare Enveric Biosciences Inc (ENVB) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Logitech International SA — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Logitech International SA trades at $101.34 (market cap $14.63B). The key difference: Logitech International SA is far larger — about 2186.8× Enveric Biosciences Inc's market cap, and Logitech International SA pays a 1.62% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Logitech International SA for 92 Days on average.
| ENVB | LOGI | |
|---|---|---|
Market Cap | $6.69M | $14.63B |
Volume | 41,141 | 440,764 |
Sector | Health | Technology |
52-Week High | $10.80 | $126.69 |
52-Week Low | $1.27 | $85.84 |
Typical Hold Time | 14 Days | 92 Days |
Enterprise Value | -$1.60M | $12.96B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Logitech (LOGI) trades at $101.50, down 0.89% today, with a bullish technical signal and strong fundamental performance. Recent earnings beats, including Q2 2026 EPS of $1.85 versus $1.26 expected, highlight operational strength. The company maintains robust profitability with a net margin of 16.28% and ROE of 35.29%, supported by new product launches like the Zone Vibe Pro headset and gaming partnerships.
Outlook remains positive with analyst consensus target of $107, offering ~5% upside, though risks include chip shortages and competitive pressures. Revenue growth is projected to reach $4.9B in 2026, but investor sentiment is mixed amid macroeconomic headwinds. The stock's valuation at P/E 18.75 appears reasonable given earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
